Sid Gilman M.D.
| 300 North Ingalls St. 3D15 |
| Ann Arbor, MI 48109 |
I am investigating the autonomic, visual and olfactory disorders found in early Parkinson’s disease utilizing clinical evaluations coupled with positron emission tomography (PET) studies of nigrostriatal presynaptic monoaminergic innervation utilizing [11C]DTBZ and PET studies of postganglionic sympathetic cardiac innervation utilizing [11C]PMP.
Additional investigations are focused on multiple system atrophy, including the natural history of progression, the efficacy of treatment in a pilot study, and the post-ganglionic sympathetic innervation of the heart utilizing PET with [11C]HED.
Another set of investigations concerns Alzheimer's disease, testing the hypothesis that in the early stages of the disease, the larger the area of cortical hypometabolism the faster the rate of progression of the disease. This study utilizes PET with [18F]FDG, [11C]DTBZ, and [11C]PIB.
In studies with Cortex Pharmaceuticals, I am studying the effects of an Ampakine upon recent memory in patients with Alzheimer's disease, studying cerebral blood flow changes during neuropsychological testing using [15O)H2O.
In studies with Elan and Wyeth pharmaceutical companies, I am serving as Chair of the Safety Monitoring Committee for passive immunotherapy for Alzheimer's disease. I am currently analyzing the results of a Phase II investigation of Bapineuzumab, a monoclonal antibody directed against deposits of beta-amyloid in the brain of patients with mild to moderate Alzheimer’s disease.
Vilensky JA, Mukhamedzyanov RZ, Gilman S. Encephalitis lethargica in the Soviet Union. Eur Neurol 2008;60:113-121.
Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JCS, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimer’s & Dementia 2008;4(3)156-163.
Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA. Differentiating Alzheimer disease from dementia with Lewy bodies and Parkinson disease with [11C]DTBZ PET. Alzheimer’s & Dementia 2008;4(1) (Suppl 1):S67-S76.
Burns JW, Consens FB, Little RJ, Angell KJ, Gilman S, Chervin RD. EMG variance during polysomnography as an assessment for REM sleep behavior disorder. Sleep 2007;30(12):1771-1778.
May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, MD, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW, and the North American Multiple System Atrophy Study Group. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 2007;22(16):2371-2377.
Vilensky JA, Foley P, Gilman S. Children and encephalitis lethargica. Pediatric Neurology 2007;37(2):79-84.
Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW, and the North American Multiple System Atrophy Study Group. The G2019S mutation in the leucine rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 2007;22(4):546-549.
Vilensky JA, Gilman S. Encephalitis lethargica: could this disease be recognized if the epidemic recurred? Prac Neurol 2006;6:360-367.
Zhukareva V, Joyce S, Schuck T, Van Deelin V, Hurtig H, Albin R, Gilman S, Chin S, Miller B, Trojanowski JQ, Lee VM-Y. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. Ann Neurol 2006;60:335-345.
Raffel DM, Koeppe RA, Little R, Wang C-N, Liu S, Junck L, Heumann M, Gilman S. PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J Nucl Med 2006;47:1-9.
Gilman S. Pharmacologic management of ischemic stroke: relevance to stem cell therapy. Exp Neurol 2006;199:28-36.
Gilman S. Time course and outcome of recovery from stroke: relevance to stem cell treatment. Exp Neurol 2006;199:37-41.
183. Vilensky JA, Gilman S, Casey K. Sir Victor Horsley, Mr. John Marshall, the nervi nervorum and pain: more than a century ahead of its time. Arch Neurol 2005;62:499-501.
184. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo J-M. Clinical effects of A-beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
185. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of A-beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572.
186. Consens FB, Chervin RD, Koeppe RA, Little R, Liu S, Junck L, Angell K, Heumann M, Gilman S. Validation of a polysomnographic score for REM sleep behavior disorder (RBD). Sleep 2005;28:993-997.
187. Vilensky JA, Sinish PR, Stone JL, Gilman S. The publications of Sir Victor Horsley: a listing and an assessment. Neurosurgery. 2005;57:581-584.
188. Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T. The North American multiple system atrophy study group. J Neural Transm 2005 Dec;112:1687-1694.
189. Colosimo C, Gilman S, Quinn N, Wenning GK. Preface - Special issue: Multiple system atrophy. J Neural Transm 2005;112:1601-1603.
190. Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. J Neural Transm 2005;112:1647-1655.
191. Koeppe RA, Gilman S, Joshi A, Liu S, Little, R, Junck, L, Heumann M, Frey KA, Albin RL. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 2005;46:936-944.
192. Vilensky JA, Goetz C, Gilman S. Movement disorders associated with encephalitis lethargica: A video compilation. Mov Disord 2006;21:1-8.
193. Zipes DP, Zvaifler NJ, Glassock RJ, Gilman S, Muñoz A, Gogolak V, Gordis L, Dedon PC, Guengerich FP, Wasserman SI, Witztum JL, Wogan GN. Analysis of the efficacy and safety of Rosuvastatin: an independent analysis of risks and benefits. Medscape General Medicine 2006;8:73 available at http://medgenmed.medscape.com/viewarticle/533930.
Find more publications by Dr.Sid Gilman